Gilead Sciences, Inc.

1477 articles with Gilead Sciences, Inc.

• Gilead and Nurix Establish Strategic Collaboration to Develop Novel Therapies for Cancer and Other Diseases

  6/19/2019

  Collaboration will Leverage Nurix’s Proprietary Drug Discovery Platform to Identify Novel Agents that Induce Degradation of Specified Drug Targets

• 

  Gilead Strikes $2.48 Billion Deal with Nurix to Focus on Protein Degradation

  6/19/2019

  The focus will be on discovering drugs that use the body’s natural protein control processes.
• 

  AbCellera and Gilead Forge Infectious Disease Pact

  6/13/2019

  AbCellera will use its technology to look for ultra-rare antibodies with specific properties defined by Gilead.
• 

  Kite Pharma Presents Updated Safety Data for Hard-to-Treat Blood Cancers

  6/4/2019

  At the American Society of Clinical Oncology meeting in Chicago, Kite presented updated safety data from the ZUMA-1 trial that introduced a regimen of steroids to CAR-T patients who show early signs of neurologic events reduces the safety concerns associated the CAR-T treatment.

• Kite Announces New Yescarta® Data From ZUMA-1

  6/3/2019

  Sub-Population Analysis Demonstrates High Rates of Durable Response and Overall Survival Regardless of Age at Two Years Post-Treatment

• HitGen Enters into DNA-Encoded Library Based Drug Discovery Research Collaboration with Gilead Sciences

  6/3/2019

  HitGen Inc. announced that it has entered into a drug discovery research collaboration with Gilead Sciences to identify potential small molecule leads against targets of interest to Gilead.

• Biocartis and Kite Sign Agreement for Development of Assays supporting Kite’s Therapies

  6/1/2019

  Biocartis Group NV, an innovative molecular diagnostics company, announced that it has entered into a Master Development and Commercialization Agreement with Kite, a Gilead Company.

• Kite and Humanigen Announce Clinical Collaboration to Evaluate Investigational Combination of Yescarta® (Axicabtagene Ciloleucel) with Lenzilumab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

  5/31/2019

  Kite, a Gilead Company, and Humanigen, Inc. (HGEN) announced today the formation of a clinical collaboration to conduct a Phase 1/2 study of lenzilumab, an investigational anti-GM-CSF monoclonal antibody, with Yescarta® in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

• Gilead Sciences Appoints Johanna Mercier as Chief Commercial Officer

  5/29/2019

  Gilead Sciences, Inc. (NASDAQ: GILD) today announced that Johanna Mercier will join the company as Chief Commercial Officer, and will become a member of the company’s senior leadership team.

• Gilead and Galapagos to Present Latest Data on Filgotinib at the Annual European Congress of Rheumatology (EULAR 2019)

  5/29/2019

  Phase 3 FINCH 1 and FINCH 3 Data of Filgotinib in Rheumatoid Arthritis to Be Featured in Opening Plenary and Late Breaker Sessions

• Gilead Sciences to Present at the Jefferies 2019 Global Healthcare Conference on Wednesday, June 5

  5/21/2019

  Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Daniel O’Day, Gilead’s Chairman and Chief Executive Officer, will participate in a fireside chat at the Jefferies 2019 Global Healthcare Conference in New York on Wednesday, June 5 at 11:30 a.m. Eastern Time.

• 

  Legal Decision Could Open the Doors for Truvada Generic Competition One Year Early, Gilead Says

  5/13/2019

  Gilead's Truvada is expected to lose patent protection in 2021, but a recent court decision in Europe could change that.
• 

  Gilead Pledges 2.4 Million Annual Dose Donations of Drug to End HIV in the U.S.

  5/10/2019

  The company is pledging to support a goal to end HIV in the U.S. by 2030 announced by the president during the State of the Union this year.

• Gilead Sciences to Provide Free Truvada for PrEP® to Support U.S. Initiative to End the HIV Epidemic

  5/9/2019

  Donation Provides up to 2.4 Million Free Bottles Annually to Uninsured Americans at Risk for HIV

• 

  The Best of the Rest: A Roundup of Life Science Stories

  5/9/2019

  Today has been marked by a wide range of life science and biopharma stories. Here’s a broader look at some of the top stories.

• HOOKIPA Achieves Research Milestone in HBV Collaboration and License Agreement with Gilead

  5/8/2019

   HOOKIPA Pharma Inc. (NASDAQ: HOOK), a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform, today announced that it has achieved a further research milestone in its collaboration and license agreement with Gilead Sciences, Inc.

• 

  Gilead and Goldfinch Bio Enter $2 Billion-Plus Partnership to Develop Kidney Disease Drugs

  5/8/2019

  Under the terms of the deal, Gilead holds exclusive options to license worldwide rights to specific products directed toward targets coming out of Goldfinch’s proprietary Kidney Genome Atlas.

• Gilead Sciences to Present at the Bank of America Merrill Lynch 2019 Health Care Conference on Tuesday, May 14

  5/6/2019

  Webcast Available Through Gilead Corporate Website

• 

  Gilead’s HIV Drugs Drive Company’s Revenues in Q1 Report

  5/3/2019

  Despite continued slumps in sales of its hepatitis C medications, Gilead Sciences saw a robust first quarter, with earnings up nearly 28 percent. That was good news as new Chief Executive Officer Dan O’Day marked his first full quarter with the California-based company.

• Gilead Sciences Announces Second Quarter 2019 Dividend

  5/2/2019

  The dividend is payable on June 27, 2019, to stockholders of record at the close of business on June 14, 2019.